Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Xpovio

(Selinexor)

Phase 3Small molecule

KKaryopharm Therapeutics Inc

Selinexor is used to treat certain types of cancer, including multiple myeloma and lymphoma, by blocking a protein that helps cancer cells survive and grow.[1] Xpovio is currently being investigated across 57 indications[3], with its most advanced program in Phase 3.[1]

Xpovio is one of 1112 small molecule programs targeting Glioma. It is currently in Phase 3.

57

Indications

149

Total Trials

62

Active Trials

1,111

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

11

Patents

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

ParagangliomaActive, not recruiting

Salivary Gland CancerActive, not recruiting

Unspecified Peripheral T-Cell LymphomaActive, not recruiting

Lung CancerActive, not recruiting

ThrombocytopeniaActive, not recruiting

Central Nervous System LymphomaActive, not recruiting

Extranodal Nasal NK/T Cell LymphomaActive, not recruiting

LymphomaActive, not recruiting

Cutaneous T-Cell LymphomaActive, not recruiting

GliomaPhase 1/Phase 2

Active, not recruiting

ParagangliomaPhase 2

Active, not recruiting

Salivary Gland CancerPreclinical

Active, not recruiting

Unspecified Peripheral T-Cell LymphomaPhase 1

Active, not recruiting

Lung CancerPhase 1/Phase 2

Active, not recruiting

ThrombocytopeniaPhase 2

Active, not recruiting

Central Nervous System LymphomaPhase 1/Phase 2

Active, not recruiting

Extranodal Nasal NK/T Cell LymphomaPhase 2

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

Cutaneous T-Cell LymphomaPhase 2

Active, not recruiting

Showing 10 of 56 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Xpovio

KKaryopharm Therapeutics Inc

Trodelvy

Gemzar

GGynecologic Oncology Group

Blenoxane

Bristol-Myers Squibb

Zolymbus

Recentin

NNational Cancer Institute (NCI)

Avastin

Neoadjuvant Therapy

SSun Yat-sen University

Perflutren Lipid Microcpheres

TThomas Jefferson University

Tianeptine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Multiple Myeloma

NCT03589222

Phase 2Active, not recruiting

Myelofibrosis

NCT04562870

Phase 2Active, not recruiting

Multiple Myeloma

NCT06169215

Q4 2026

Phase 2Not yet recruiting

Myeloid Neoplasm

NCT06900088

Active, not recruiting

Multiple Myeloma

NCT05954780

Phase 2Active, not recruiting

Multiple Myeloma

NCT04925193

Clinical

Trials by Indication[1]

Multiple Myeloma31 trials

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Active, not recruiting·—·Phase 2·NCT04756401·52 enrolled

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Active, not recruiting·MMayo Clinic·Phase 1/2·NCT04764942·39 enrolled

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT02186834·28 enrolled

Show 28 more trials

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Active, not recruiting·UUS Oncology Research·Phase 2·NCT04782687·73 enrolled

Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma

No longer available·MMasonic Cancer Center, University of Minnesota··NCT03850704

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Active, not recruiting·UUniversity of Colorado, Denver·Phase 2·NCT04925193·18 enrolled

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT07138209·228 enrolled

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT02780609·22 enrolled

Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma

Withdrawn·KKaryopharm Therapeutics Inc·Phase 2·NCT02628704

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Active, not recruiting·EEuropean Myeloma Network B.V.·Phase 3·NCT05028348·117 enrolled

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT05900882·35 enrolled

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Recruiting·UUniversity of Miami·Phase 2·NCT05530421·33 enrolled

Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Withdrawn·KKaryopharm Therapeutics Inc·Phase 1/2·NCT02389543

Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

Recruiting·WWashington University School of Medicine·Phase 1·NCT07200102·20 enrolled

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Suspended·HHackensack Meridian Health·Phase 2·NCT04661137·96 enrolled

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Active, not recruiting·PPETHEMA Foundation·Phase 2·NCT03589222·62 enrolled

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Recruiting·UUniversity of Rochester·Phase 2·NCT05597345·15 enrolled

Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Withdrawn·WWashington University School of Medicine·Phase 2·NCT05820763

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

Not yet recruiting·NNatalie Callander·Phase 1/2·NCT07479979·62 enrolled

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

Completed·KKaryopharm Therapeutics Inc·Phase 3·NCT03110562·402 enrolled

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma

Active, not recruiting·MMayo Clinic·Phase 1·NCT04640779·22 enrolled

Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·UUniversity of Chicago·Phase 1·NCT02199665·52 enrolled

A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma

Unknown status·CChunrui Li·Phase 1·NCT05201118·20 enrolled

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Unknown status·OOncotherapeutics·Phase 1·NCT04519476·22 enrolled

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Recruiting·XXia Zhongjun·Phase 1/2·NCT05422027·42 enrolled

Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma

Active, not recruiting·IiOMEDICO AG··NCT05954780·75 enrolled

Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT04843579·4 enrolled

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Recruiting·KKaryopharm Therapeutics Inc·Phase 1/2·NCT02343042·300 enrolled

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Recruiting·KKaryopharm Therapeutics Inc·Phase 2·NCT04414475·127 enrolled

A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06169215·70 enrolled

A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)

Recruiting· AbbVie logo

AbbVie·Phase 3·NCT06158841·380 enrolled

Acute Myeloid Leukemia12 trials

Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results

Recruiting·SShanghai Tong Ren Hospital·Phase 2·NCT05736978·58 enrolled

Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia

Completed·UUniversity of Chicago·Phase 1·NCT02573363·25 enrolled

A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia

Recruiting·SShanghai Tong Ren Hospital·Phase 2·NCT05736965·58 enrolled

Show 9 more trials

Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·BBhavana Bhatnagar·Phase 1·NCT02093403·25 enrolled

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT04898894·37 enrolled

Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia

Completed·WWashington University School of Medicine·Phase 1/2·NCT02416908·40 enrolled

Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·AAlice Mims·Phase 1·NCT02299518·23 enrolled

Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT03071276·37 enrolled

A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Completed·GGSO Global Clinical Research BV·Phase 2·NCT02249091·42 enrolled

Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT02530476·17 enrolled

Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients

Active, not recruiting·WWake Forest University Health Sciences·Phase 2·NCT02835222·57 enrolled

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Recruiting·SShanxi Bethune Hospital·Phase 3·NCT05726110·50 enrolled

Lymphoma7 trials

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT02436707·129 enrolled

Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma

Recruiting·SSamsung Medical Center·Phase 1/2·NCT06552559·37 enrolled

Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma

Completed·NNational Cancer Centre, Singapore·Phase 1·NCT03212937·11 enrolled

Show 4 more trials

A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma

Unknown status·RRuijin Hospital··NCT05852028·250 enrolled

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT05322330·20 enrolled

A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP

Completed·TThe Lymphoma Academic Research Organisation·Phase 1·NCT02741388·39 enrolled

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

Active, not recruiting·BBarbara Ann Karmanos Cancer Institute·Phase 1/2·NCT03147885·43 enrolled

Diffuse Large B-Cell Lymphoma5 trials

Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

Recruiting·LLi Zhiming·Phase 2·NCT05422066·50 enrolled

A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

Recruiting·CChengdu Zenitar Biomedical Technology Co., Ltd·Phase 3·NCT07011056·390 enrolled

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Withdrawn·KKaryopharm Therapeutics Inc·Phase 1/2·NCT04607772

Show 2 more trials

Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma

Unknown status·—·Phase 4·NCT05786989·32 enrolled

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Active, not recruiting·KKaryopharm Therapeutics Inc·Phase 2·NCT02227251·244 enrolled

Glioma3 trials

Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas

Terminated·KKaryopharm Therapeutics Inc·Phase 2·NCT01986348·76 enrolled

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

Completed·CChildren's Oncology Group·Phase 1·NCT02323880·59 enrolled

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT05099003·132 enrolled

72 more indications

COVID-193 trials

Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection

Completed·KKaryopharm Therapeutics Inc·Phase 2·NCT04349098·190 enrolled

Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19

Withdrawn·KKaryopharm Therapeutics Inc·Phase 2·NCT04355676

COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;

Completed·PPeter MacCallum Cancer Centre, Australia·Phase 3·NCT04534725·441 enrolled

Myelofibrosis3 trials

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

Active, not recruiting·KKaryopharm Therapeutics Inc·Phase 3·NCT04562389·353 enrolled

Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

Terminated·UUniversity of Utah·Phase 2·NCT03627403·17 enrolled

A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physician's Choice in Patients With Previously Treated Myelofibrosis

Active, not recruiting·KKaryopharm Therapeutics Inc·Phase 2·NCT04562870·112 enrolled

Chemotherapy3 trials

ATG-010(Selinexor) in Combination With Chemotherapy in RRMM

Unknown status·—·Phase 2·NCT04877275·50 enrolled

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Suspended·NNational Cancer Institute (NCI)·Phase 1/2·NCT05432804·97 enrolled

Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy

Terminated·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT06449482·6 enrolled

Myelodysplastic Syndrome3 trials

Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

Completed·UUniversity of Chicago·Phase 1·NCT02485535·12 enrolled

Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT02212561·19 enrolled

Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients

Withdrawn·KKaryopharm Therapeutics Inc·Phase 2·NCT02431351

Small Cell Lung Cancer2 trials

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07172412·165 enrolled

Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer

Terminated·EErin Bertino·Phase 2·NCT02351505·1 enrolled

Breast Cancer2 trials

Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT02402764·10 enrolled

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Recruiting·NNational University Hospital, Singapore·Phase 1/2·NCT05035745·63 enrolled

Prostate Cancer2 trials

SHIP (Selinexor in Hormone Insensitive Prostate Cancer)

Terminated·KKaryopharm Therapeutics Inc·Phase 2·NCT02146833·20 enrolled

Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

Terminated·UUniversity of California, San Francisco·Phase 2·NCT02215161·14 enrolled

Acute Leukemia2 trials

Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT05951855·42 enrolled

Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

Unknown status·TThe First Affiliated Hospital of Soochow University·N/A·NCT05805072·20 enrolled

Endometrial Cancer2 trials

Maintenance with Selinexor/Placebo After Combination Chemotherapy in Participants with Endometrial Cancer [SIENDO]

Active, not recruiting·KKaryopharm Therapeutics Inc·Phase 3·NCT03555422·263 enrolled

Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02269293·23 enrolled

Glioblastoma2 trials

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Terminated·KKaryopharm Therapeutics Inc·Phase 1/2·NCT04421378·74 enrolled

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04216329·11 enrolled

Dexamethasone2 trials

A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02831686·18 enrolled

Selinexor in Combination With Thalidomide and Dexamethasone in RRMM

Unknown status·LLi Zheng·Phase 1/2·NCT04891744·48 enrolled

Melanoma2 trials

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

Terminated·KKaryopharm Therapeutics Inc·Phase 2·NCT04768881·15 enrolled

Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery

Completed·KKari Kendra·Phase 1·NCT02120222·8 enrolled

Metastatic Colorectal Cancer2 trials

Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer

Terminated·GGSO Global Clinical Research BV·Phase 1·NCT02384850·10 enrolled

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

Terminated·KKaryopharm Therapeutics Inc·Phase 2·NCT04854434·13 enrolled

EBV1 trial

Golidocitinib Combined With Selinexor for CAEBVD

Recruiting·—·Phase 2/3·NCT07369739·28 enrolled

Malignancies1 trial

Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies

Completed·KKaryopharm Therapeutics Inc·Phase 2·NCT02025985·116 enrolled

Methylprednisolone1 trial

A Trial of Selinexor, Ruxolitinib and Methylprednisolone

Recruiting·OOncotherapeutics·Phase 1·NCT06225310·30 enrolled

Gastrointestinal Stromal Tumor1 trial

Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)

Unknown status·GGrupo Espanol de Investigacion en Sarcomas·Phase 1/2·NCT04138381·30 enrolled

Pancreatic Cancer1 trial

Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

Completed·MMohammed Najeeb Al Hallak·Phase 1/2·NCT02178436·15 enrolled

Salivary Gland Cancer1 trial

A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

Completed·UUniversity Health Network, Toronto·N/A·NCT02069730·114 enrolled

Refractory1 trial

Selinexor Treatment of Refractory Myeloma

Completed·KKaryopharm Therapeutics Inc·Phase 2·NCT02336815·202 enrolled

DLBCL1 trial

Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients

Unknown status·SSun Yat-sen University·Phase 1/2·NCT05577364·54 enrolled

Pancreatic Tumors1 trial

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Completed·—·Phase 2·NCT02250885·14 enrolled

Advanced Sarcoma1 trial

Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma

Withdrawn·MMatthew Ingham·Phase 1·NCT03880123

Induction Chemotherapy1 trial

Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML

Active, not recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 2·NCT07437170·10 enrolled

Veterans1 trial

Telehealth-based Symptom Management for Veterans Treated With Selinexor

Active, not recruiting·—··NCT06452446·20 enrolled

Urothelial Carcinoma1 trial

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Terminated·MMamta Parikh·Phase 1/2·NCT04856189·4 enrolled

Older Patients1 trial

Selinexor (KPT-330) in Older Patients With Relapsed AML

Completed·KKaryopharm Therapeutics Inc·Phase 2·NCT02088541·317 enrolled

Amyloidosis1 trial

Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease

Withdrawn·WWeill Medical College of Cornell University·Phase 1·NCT04984330

Richter's Transformation1 trial

Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation

Terminated·KKaryopharm Therapeutics Inc·Phase 2·NCT02138786·27 enrolled

Ovarian Cancer1 trial

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Recruiting·LLoyola University·Phase 2·NCT05983276·40 enrolled

Advanced or Metastatic Solid Tumor1 trial

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

Completed·KKaryopharm Therapeutics Inc·Phase 1·NCT01607905·192 enrolled

Safety and Efficacy1 trial

A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL

Recruiting·FFudan University·Phase 1/2·NCT06966154·68 enrolled

Hepatic Impairment1 trial

Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

Completed·KKaryopharm Therapeutics Inc·Phase 1/2·NCT04256707·126 enrolled

Maintenance Treatment1 trial

An Open, Single Center, Non-randomized, Single Arm Clinical Study of Evaluating the Efficacy of Selinexor in the Maintenance Treatment of PTCL

Unknown status·TThe First Hospital of Jilin University·Phase 2/3·NCT05822050·20 enrolled

Advanced Malignancies1 trial

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT02419495·221 enrolled

Central Nervous System Lymphoma1 trial

A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1/2·NCT06556199·38 enrolled

Thymic Carcinoma1 trial

Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma

Unknown status·MMorten Mau-Soerensen·Phase 2·NCT03466827·25 enrolled

JAK Inhibitor1 trial

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

Not yet recruiting·JJohn Mascarenhas·Phase 2·NCT07447817·26 enrolled

Lenalidomide1 trial

Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM

Unknown status·JJuan Du·Phase 2·NCT04941937·90 enrolled

Advanced Soft-tissue Sarcoma1 trial

Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)

Recruiting·AAsociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas·Phase 2·NCT06114004·88 enrolled

Squamous Cell Carcinoma1 trial

Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas

Terminated·KKaryopharm Therapeutics Inc·Phase 2·NCT02213133·45 enrolled

Thrombocytopenia1 trial

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Recruiting·KKaryopharm Therapeutics Inc·Phase 2·NCT05980806·58 enrolled

First Line Therapy1 trial

Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

Recruiting·SSun Yat-sen University·Phase 2·NCT06517511·42 enrolled

Newly Diagnosed1 trial

Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

Active, not recruiting·IIda Bruun Kristensen·Phase 2·NCT04717700·50 enrolled

Bispecific Antibody1 trial

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

Recruiting·—·Phase 2·NCT06822972·27 enrolled

Myelodysplastic Syndromes1 trial

Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02228525·25 enrolled

Soft Tissue Sarcoma1 trial

Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas

Completed·UUniversity Health Network, Toronto·Phase 1·NCT03042819·25 enrolled

Cutaneous T-cell lymphoma1 trial

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

Terminated·KKaryopharm Therapeutics Inc·Phase 2·NCT02314247·16 enrolled

Sarcoma1 trial

A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients

Completed·UUniversity Health Network, Toronto·Phase 1·NCT04811196·56 enrolled

ESS1 trial

Karyopharm Expanded Access Program for Selinexor

Available·KKaryopharm Therapeutics Inc··NCT07215832

Immunotherapy1 trial

Second-line Immunotherapy for ES-SCLC

Recruiting·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT06853678·30 enrolled

Diabetic Foot1 trial

Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients

Withdrawn·KKaryopharm Therapeutics Inc·Phase 1/2·NCT02367690

Adenocarcinoma1 trial

Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT02283359·3 enrolled

Myeloma1 trial

Selinexor, Cyclophosphamide and Prednisone in Myeloma

Completed·UUniversity of Leeds·Phase 2·NCT06212596·66 enrolled

Chronic Lymphocytic Leukemia1 trial

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Completed·JJennifer Woyach·Phase 1·NCT02303392·34 enrolled

Myeloid Neoplasm1 trial

Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06900088·20 enrolled

Osteosarcoma1 trial

Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma

Recruiting·GGrupo Espanol de Investigacion en Sarcomas·Phase 1·NCT04595994·14 enrolled

Relapsed/Refractory1 trial

Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH

Active, not recruiting·—·Phase 2·NCT07204041·40 enrolled

Malignant Rhabdoid Tumor1 trial

Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors

Withdrawn·SSt. Jude Children's Research Hospital·Phase 1·NCT05952687

Endometrial Carcinoma1 trial

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Recruiting·KKaryopharm Therapeutics Inc·Phase 3·NCT05611931·276 enrolled

Non-Small Cell Lung Cancer1 trial

Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT03095612·41 enrolled

Wilms tumor1 trial

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05985161·45 enrolled

Hematologic Malignancies1 trial

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

Completed·SSanjay Mohan·Phase 1·NCT03955783·78 enrolled

Liposarcoma1 trial

Selinexor in Advanced Liposarcoma

Completed·KKaryopharm Therapeutics Inc·Phase 2/3·NCT02606461·342 enrolled

Untreated AML1 trial

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT02403310·21 enrolled

Refractory AML1 trial

Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML

Completed·PPETHEMA Foundation·Phase 1·NCT03661515·16 enrolled

Lung Cancer1 trial

Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer

Withdrawn·EErin Bertino·Phase 1/2·NCT02536495

Neoplasm1 trial

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Recruiting·SSt. Jude Children's Research Hospital·Preclinical·NCT06239272·139 enrolled

Relapsed/Refractory Diffuse Large B-cell Lymphoma1 trial

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)

Active, not recruiting·KKaryopharm Therapeutics Inc·Preclinical·NCT04442022·501 enrolled

Alveolar Soft Part Sarcoma1 trial

A Phase 2 Study of Atezolizumab With Selinexor in Alveolar Soft Part Sarcoma (AXIOM)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05333458·27 enrolled

Pancreatic Ductal Carcinoma1 trial

ADOPT: Adaptive Organoid-Based Precision Therapy Study in Pancreatic Cancer - A Prospective Single-Arm Phase II Trial

Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT06813079·25 enrolled

Unspecified3 trials

Selinexor Combination Ph 1 Study

Withdrawn·MMartin Gutierrez·Phase 1/2·NCT05177276

Twice-per-weekSelinexor, 2 Days Melphalan

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 3·NCT06613035·126 enrolled

Selinexor in Combination With MTX+Ritu to Treat R/R CNSL

Recruiting·—·Phase 1/2·NCT05698147·30 enrolled

Regulatory

FDA Approval Timeline[4]

Mar 10, 2025

XPOVIO

NDA NDA212306

Sources

References

[1]
ClinicalTrials.gov — 149 trial records for Selinexor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Selinexor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Selinexor. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA212306). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Xpovio. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Karyopharm Therapeutics Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Exportin-1 Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKaryopharm Therapeutics Inc

Patent Landscape[5]

Patent Cliff

Jul 26, 2032

Earliest patent expiration — generic entry possible after this date

Patent #Expires

9079865Jul 26, 2032

10544108Jul 26, 2032

11034660Jul 26, 2032

11787771Jul 26, 2032

12291508Jul 26, 2032

6 more patents

9714226Jul 26, 2032

8999996Jul 3, 2033

10519139Aug 14, 2035

11746102Aug 14, 2035

11753401Aug 14, 2035

11807629Aug 14, 2035

Related News